Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Products under Development by Stage of Development | 9 | 1 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Products under Development by Therapy Area | 10 | 1 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Products under Development by Indication | 11 | 1 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Products under Development by Companies | 14 | 2 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Products under Development by Universities/Institutes | 16 | 2 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Companies Involved in Therapeutics Development | 24 | 7 |
| Biomics Biotechnologies Co., Ltd. | 24 | 1 |
| Bioneer Corporation | 25 | 1 |
| Boehringer Ingelheim GmbH | 26 | 1 |
| CureVac GmbH | 27 | 1 |
| MimiVax, LLC | 28 | 1 |
| Optimum Therapeutics, LLC | 29 | 1 |
| Polyplus-Transfection SA | 30 | 1 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Drug Profiles | 31 | 22 |
| Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer Drug Profile | 31 | 1 |
| Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology Drug Profile | 32 | 1 |
| Antisense RNAi Oligonucleotide to Inhibit Survivin for Solid Tumors Drug Profile | 33 | 1 |
| Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer Drug Profile | 34 | 2 |
| BI-1361849 Drug Profile | 36 | 2 |
| BKM-1644 Drug Profile | 38 | 1 |
| BKM-1740 Drug Profile | 39 | 1 |
| C-10M Drug Profile | 40 | 1 |
| Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma Drug Profile | 41 | 1 |
| Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer Drug Profile | 42 | 1 |
| CV-9201 Drug Profile | 43 | 2 |
| FL-118 Drug Profile | 45 | 2 |
| MX-106 Drug Profile | 47 | 1 |
| SurVaxM Drug Profile | 48 | 2 |
| UC-112 Drug Profile | 50 | 1 |
| Vaccine for Lymphoma and Colon Carcinoma Drug Profile | 51 | 1 |
| Vaccine for Oncology Drug Profile | 52 | 1 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Dormant Projects | 53 | 3 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Discontinued Products | 56 | 2 |
| Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Featured News &Press Releases | 58 | 11 |
| May 31, 2016: Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID to Treat Rare Blood Cancer | 58 | 1 |
| Sep 09, 2015: Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study | 58 | 1 |
| Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies | 59 | 1 |
| Apr 21, 2015: SurVaxM Phase I Completed | 60 | 1 |
| Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer | 61 | 1 |
| Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent | 62 | 1 |
| Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent | 63 | 1 |
| Nov 04, 2013: CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer | 64 | 1 |
| Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent | 64 | 1 |
| Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent | 65 | 1 |
| Nov 07, 2011: CureVac Presents Results Of Phase I/IIa Trial In Non-Small Cell Lung Cancer With CV9201 At 26th Annual SITC Meeting | 66 | 1 |
| Jun 10, 2011: CureVac Presents Promising New Data For Lung Cancer Vaccine CV9201 At ASCO Conference | 66 | 1 |
| Jun 16, 2010: CureVac Starts Phase IIa With mRNA Immunotherapeutic In Non-Small Cell Lung Cancer | 67 | 1 |
| May 26, 2009: CureVac Begins Clinical Study With mRNA Vaccine In Non-Small Cell Lung Cancer | 67 | 2 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |